M9466 + abiraterone acetate + prednisone + prednisolone

M9466 + abiraterone acetate + prednisone + prednisolone is a pharmaceutical combination comprising four agents: M9466 (details not found in current data, likely a developmental or experimental agent), **abiraterone acetate** (a small molecule CYP17 inhibitor blocking androgen production), **prednisone** (a synthetic glucocorticoid corticosteroid), and **prednisolone** (an active metabolite and corticosteroid). Abiraterone acetate is used for metastatic prostate cancer, specifically castration-resistant and castration-sensitive forms, and mitigates androgen-driven cancer growth by inhibiting steroidogenesis. Prednisone and/or prednisolone are combined to offset mineralocorticoid excess from abiraterone-induced CYP17 blockade, and provide anti-inflammatory and immunosuppressive effect[1][2][4][5][6]. This multi-agent combination could be under investigation for advanced prostate cancer, leveraging complementary mechanisms to suppress disease progression and manage adverse effects.

Other names

M9466M-9466M 9466